A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition

References

• . International Diabetes Federation. Diabetes. http://atlas.idf-bxl.org/content/diabetes. Accessed January 12, 2011
   Google Scholar
• . Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443–453
   PubMed Web of Science ®Google Scholar
• . CDC National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed April 14, 2011
   Google Scholar
• . Centers for Disease Control and Prevention. Number of people with diabetes increases to 24 million. http://www.cdc.gov/media/pressrel/2008/r080624.htm. Accessed January 12, 2011
   Google Scholar
• . Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169–3176
   PubMed Web of Science ®Google Scholar
• . Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76( suppl 5):S12–S19
   PubMedGoogle Scholar
• . Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3–19
   PubMed Web of Science ®Google Scholar
• . Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52(12):2867–2873
   PubMed Web of Science ®Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Ohkubo Y, Kishikawa H, Araki E,. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422–1426
   PubMedGoogle Scholar
• . Skyler JS, Bergenstal R, Bonow RO,. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med. 2009;76( suppl 5):S4–S11
   PubMedGoogle Scholar
• . Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc. 2003;78(4):459–467
   PubMed Web of Science ®Google Scholar
• . Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12(5):384–392
   PubMed Web of Science ®Google Scholar
• . Pijl H, Ohashi S, Matsuda M,. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154–1161
   PubMed Web of Science ®Google Scholar
• . Standards of medical care in diabetes–2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27(7):1064–1073
   Google Scholar
• . Grant RW, Buse JB, Meigs JB; University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28(2):337–442
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA,; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB,; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382–391
   PubMed Web of Science ®Google Scholar
• . Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96(5):2528–2533
   PubMed Web of Science ®Google Scholar
• . Conjard A, Martin M, Guitton J, Baverel G, Ferrier B. Gluconeogenesis from glutamine and lactate in the isolated human renal proximal tubule: longitudinal heterogeneity and lack of response to adrenaline. Biochem J. 2001;360(pt 2):371–377
   PubMed Web of Science ®Google Scholar
• . Ross BD, Espinal J, Silva P. Glucose metabolism in renal tubular function. Kidney Int. 1986;29(1):54–67
   PubMed Web of Science ®Google Scholar
• . Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int. 1984;26(2):101–111
   PubMed Web of Science ®Google Scholar
• . Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol. 1999;276(1 pt 1):E78–E84
   PubMedGoogle Scholar
• . Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998;102(3):619–624
   PubMed Web of Science ®Google Scholar
• . Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282(2):E419–E427
   PubMed Web of Science ®Google Scholar
• . Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant. 2010;25(7):2041–2043
   PubMed Web of Science ®Google Scholar
• . Hediger MA, Kanai Y, You G, Nussberger S. Mammalian ion-coupled solute transporters. J Physiol. 1995;482( suppl):7S–17S
   PubMed Web of Science ®Google Scholar
• . Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397–404
   PubMed Web of Science ®Google Scholar
• . Bishop JH, Green R, Thomas S. Free-flow reabsorption of glucose, sodium, osmoles and water in rat proximal convoluted tubule. J Physiol. 1979;288:331–351
   PubMed Web of Science ®Google Scholar
• . Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32–43
   PubMed Web of Science ®Google Scholar
• . Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–141
   PubMed Web of Science ®Google Scholar
• . Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest. 1993;91(4):1810–1815
   PubMed Web of Science ®Google Scholar
• . Ferrannini E. Learning from glycosuria. Diabetes. 2011;60(3):695–696
   PubMed Web of Science ®Google Scholar
• . Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125–129
   PubMed Web of Science ®Google Scholar
• . Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28(1):101–109
   PubMed Web of Science ®Google Scholar
• . Freitas HS, Anhe GF, Melo KF,. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149(2):717–724
   PubMed Web of Science ®Google Scholar
• . Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8(6):943–948
   PubMed Web of Science ®Google Scholar
• . Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434
   PubMed Web of Science ®Google Scholar
• . Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004;19(9):2394–2396
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1991;87(2):561–570
   PubMed Web of Science ®Google Scholar
• . Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510–1515
   PubMed Web of Science ®Google Scholar
• . Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875–883
   PubMed Web of Science ®Google Scholar
• . Han S, Hagan DL, Taylor JR,. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729
   PubMed Web of Science ®Google Scholar
• . Katsuno K, Fujimori Y, Takemura Y,. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320(1):323–330
   PubMed Web of Science ®Google Scholar
• . Pfister. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011;89(4)621–625
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Komoroski B, Vachharajani N, Boulton D,. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–526
   PubMed Web of Science ®Google Scholar
• . Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–519
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Kasichayanula S, Liu X, Shyu WC,. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47–54
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA,. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Sha S, Devineni D, Ghosh A,. Canagliflozin, a novel inhibitor of sodium glucose co-transporter-2, improves glucose control in subjects with type 2 diabetes and was well tolerated [abstract]. Diabetes. 2010;59( suppl 1):568-P
   Web of Science ®Google Scholar
• . Schwartz S, Morrow L, Hompesch M,. Canagliflozin improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin [abstract]. Diabetes. 2010;59( suppl 1):564-P
   Web of Science ®Google Scholar
• . Rosenstock J, Polodori D, Zhao Y,. Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin [abstract]. Diabetologia. 2010;53( suppl 1):S351
   Web of Science ®Google Scholar
• . Heise T, Seewaldt-Becker E, Macha S,. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes [abstract]. Diabetes. 2010;59( suppl 1):629-P
   Web of Science ®Google Scholar
• . Seman L, Macha S, Jones P,. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT2) inhibitor, following 8-days treatment in patients with type 2 diabetes [abstract]. Diabetes. 2010;59( suppl 1):571-P
   Web of Science ®Google Scholar
• . Ferrannini E, Seman LJ, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. The potent and highly selective sodium-glucose co-transporter (SGLT-2) inhibitor BI10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus [abstract]. Diabetologia. 2010;53( suppl 1):S351
   Web of Science ®Google Scholar
• . Schwartz S, Klasen S, Kowalski D, Akinlade B. ASP1941, a novel and selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), reduces fasting plasma glucose in type 2 diabetes mellitus patients over 28 days [abstract]. Diabetes. 2010;59( suppl 1):566P
   Web of Science ®Google Scholar
• . Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821
   PubMed Web of Science ®Google Scholar
• . Kodama S, Saito K, Yachi Y,. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737–1742
   PubMed Web of Science ®Google Scholar
• . Muller LM, Gorter KJ, Hak E,. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281–288
   PubMed Web of Science ®Google Scholar
• . Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26(2):510–513
   PubMed Web of Science ®Google Scholar
• . Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003;22( suppl 2):35–43
   PubMed Web of Science ®Google Scholar
• . Chao EC, Henry RR. SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559
   PubMed Web of Science ®Google Scholar